Updated:
Relmada Therapeutics
Sergio Traversa's Relmada Therapeutics is a publicly traded biotech structured around a single late-stage NMDA receptor antagonist for depression.
Relmada Therapeutics
Founded in 2013 and headquartered in Coral Gables, Florida, Relmada Therapeutics was assembled by CEO Sergio Traversa, a pharmaceutical industry veteran whose prior ventures include the infectious disease company Pharmasset. The firm was structured from the outset to advance therapies targeting central nervous system disorders, with a near-singular pipeline focus that distinguishes it from diversified biotech platforms. Public filings show the company raised capital through successive equity offerings on the Nasdaq, funding operations without a traditional venture capital anchor. Relmada's strategy concentrates on late-stage clinical development of its lead candidate, REL-1017 (esmethadone), a dextromethadone-based NMDA receptor antagonist studied as an adjunctive treatment for major depressive disorder. The company also maintained an earlier-stage asset targeting metabolic disorders, though the overwhelming allocation of financial and human capital flowed toward the REL-1017 pivotal trial program. Geographic focus remained primarily U.S.-based clinical trial sites and regulatory engagement with the FDA, with no disclosed ex-U.S. commercial infrastructure as of mid-decade. The firm does not operate a venture-studio model, make co-investments, or manage third-party capital — it is a single-asset clinical execution engine wrapped in a public-company chassis. Relmada has not publicly disclosed total capital deployed since inception, though SEC filings chronicle a series of public-market raises that funded operations and clinical trial costs. The operating entity has historically carried a lean headcount typical of a virtual or semi-virtual biotech, outsourcing manufacturing and trial management to contract research organizations. In December 2022, the company reported topline results from the RELIANCE I study showing REL-1017 failed to achieve a statistically significant improvement on the primary endpoint of depression symptoms, sending shares down sharply and signaling a fundamental reset in the pipeline trajectory (per company press release, December 2022). No adjacent philanthropic vehicles, club memberships, or real-asset arms are disclosed. The structural differentiator at Relmada is its status as a publicly traded, single-compound clinical-development vehicle — an architecture that grants retail and institutional investors direct, liquid exposure to a binary drug-approval outcome, bypassing the typical venture capital fund lifecycle. That public-markets structure also imposes a transparency burden and daily price-discovery mechanism absent in private biotech startups, making the firm's operational cadence unusually legible to outside observers through mandatory disclosures.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Coral Gables
Corporate office
Coral Gables, FL, United States
Principals
Sergio Traversa
Chief Executive Officer
Maged Shenouda
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Relmada Therapeutics?
Strategic and capital-allocation decisions are ultimately driven by CEO Sergio Traversa, who founded the company and has been the primary architect of its CNS-focused pipeline strategy. The board of directors provides governance oversight typical of a Nasdaq-listed company, with Traversa holding significant influence over trial design, regulatory strategy, and financing windows. Maged Shenouda, as CFO, manages the capital-markets and investor-relations functions that sustain the company's public-market funding model.
How is Relmada Therapeutics funded, and does it take outside limited-partner capital?
Relmada does not operate as a private fund and does not accept commitments from limited partners. Instead, it funds operations through equity offerings on the Nasdaq, making it a publicly traded operating company whose shares are available to retail and institutional investors. This structure means capital raises occur via follow-on public offerings or at-the-market facilities rather than through closed-end fund commitments, giving the entity a capital profile distinct from a life sciences venture firm.
Does Relmada participate in venture-stage investments or co-investment clubs?
No. Relmada is an operating biopharmaceutical company, not an investment firm, and does not make venture-stage allocations, join co-investment clubs, or manage third-party portfolios. All capital is directed toward the clinical development of its own pipeline assets, primarily REL-1017, with no disclosed external investing activity or off-balance-sheet investment vehicles (per SEC filings).
What is the status of Relmada's lead drug candidate?
Lead candidate REL-1017 (esmethadone) was studied as an adjunctive treatment for major depressive disorder and reached Phase 3 clinical trials. The RELIANCE I study, which read out in December 2022, failed to show a statistically significant separation from placebo on the primary endpoint, representing a material setback for the company (per company press release, December 2022). Subsequent pipeline decisions and any ongoing clinical work would be detailed in periodic SEC filings and corporate disclosures.
What sectors or therapeutic areas does Relmada target?
Relmada focuses on central nervous system disorders, specifically major depressive disorder, through its lead program. Earlier pipeline materials also referenced metabolic disorder targets, though the operational and financial focus has been overwhelmingly weighted toward neuropsychiatric indications. The firm's public disclosures and trial registrations confirm a narrow therapeutic mandate rather than a broad platform approach.
Where does Relmada derive its underlying technology, and is it in-licensed?
REL-1017 is a deuterated form of dextromethadone, itself an isomer of the well-characterized compound methadone, with Relmada holding intellectual property around its use in depression. The specific licensing and patent arrangements are detailed in the company's annual SEC filings, and the firm has maintained that its IP portfolio is structured to protect the compound through key development milestones. No third-party royalty obligations have been flagged as posing a structural threat to the asset, though detailed licensing terms remain a matter of public record in the company's 10-K.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: